ANZUP 1801/TROG 21.02 DASL-HiCaP - TROG Cancer Research

By Narelle Williams
31 January, 2022
0 Comments

Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate. A randomised phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high risk, clinically localised prostate cancer.

DASL-HiCaP is a randomised phase 3 study aiming to demonstrate that the addition of a new oral hormonal therapy, darolutamide, to the standard radiation therapy and testosterone suppression, improves the outcomes of men with localised high-risk prostate cancer.

Primary Sponsor

Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)

Collaborating Groups

Trans Tasman Radiation Oncology Group (TROG), NHMRC Clinical Trials Centre

Accrual Target

1100

Trial Chairperson

Prof Christopher Sweeney and Assoc/Prof Tamim Niazi

Trial Contact

dasl.study@sydney.edu.au

Clinical Trial Registration

Registration Link